Performance of the CareStart glucose-6-phosphate dehydrogenase (G6PD) rapid diagnostic test in Gressier, Haiti

Administering primaquine (PQ) to treat malaria patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency can pose a serious risk of drug-induced hemolysis (DIH). New easy to use point-of-care rapid diagnostic tests are being developed as an alternative to labor-intensive spectrophotometric m...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of tropical medicine and hygiene 2014-07, Vol.91 (1), p.77-80
Main Authors: von Fricken, Michael E, Weppelmann, Thomas A, Eaton, Will T, Masse, Roseline, Beau de Rochars, Madsen V E, Okech, Bernard A
Format: Article
Language:English
Subjects:
Adolescent
Antimalarials
Child
Contraindications
Enzyme Assays
Female
Glucosephosphate Dehydrogenase - analysis
Glucosephosphate Dehydrogenase - metabolism
Glucosephosphate Dehydrogenase Deficiency - complications
Glucosephosphate Dehydrogenase Deficiency - drug therapy
Glucosephosphate Dehydrogenase Deficiency - enzymology
Glucosephosphate Dehydrogenase Deficiency - parasitology
Haiti
Hemolysis
Humans
Malaria, Vivax - complications
Malaria, Vivax - drug therapy
Malaria, Vivax - enzymology
Malaria, Vivax - parasitology
Male
Plasmodium vivax
Point-of-Care Systems
Predictive Value of Tests
Primaquine
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Administering primaquine (PQ) to treat malaria patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency can pose a serious risk of drug-induced hemolysis (DIH). New easy to use point-of-care rapid diagnostic tests are being developed as an alternative to labor-intensive spectrophotometric methods, but they require field testing before they can be used at scale. This study screened 456 participants in Gressier, Haiti using the Access Bio CareStart qualitative G6PD rapid detection test compared with the laboratory-based Trinity Biotech quantitative spectrophotometric assay. Findings suggest that the CareStart test was 90% sensitive for detecting individuals with severe deficiency and 84.8% sensitive for detecting individuals with moderate and severe deficiency compared with the Trinity Biotech assay. A high negative predictive value of 98.2% indicates excellent performance in determining those patients able to take PQ safely. The CareStart G6PD test holds much value for screening malaria patients to determine eligibility for PQ therapy.
ISSN:0002-9637
1476-1645
DOI:10.4269/ajtmh.14-0100